Core Insights - Helix BioPharma Corp. announced the publication of a peer-reviewed article on the safety of L-DOS47, an unconventional antibody-drug conjugate, in treating advanced non-small cell lung cancer (NSCLC) [1][2] Company Overview - Helix BioPharma is a clinical-stage oncology company focused on developing innovative treatments for hard-to-treat cancers, with L-DOS47 as its lead candidate [4] - The company is also advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator, and GEMCEDA™, a first-in-class oral gemcitabine prodrug [5] Clinical Study Findings - The Phase I/II study of L-DOS47 demonstrated good tolerability at doses up to 13.55 µg/kg, with a median progression-free survival (PFS) of 4.1 months in the highest dosing quartile [3] - No complete or partial responses were observed, but higher doses correlated with a statistically significant extension in PFS (P=0.0203) [3] - CEACAM6 was found to be highly expressed in nearly half of NSCLC cases, suggesting its potential as a biomarker for patient selection in future trials [3] Future Development Plans - Helix plans to advance L-DOS47 into a new clinical study in combination with the PD-1 inhibitor pembrolizumab, aiming to enhance the efficacy of immunotherapies by neutralizing tumor acidity [3] - The company has received positive feedback from the FDA regarding the planned Phase I/II study in combination with pembrolizumab [3]